• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Venous thromboembolism in von Willebrand disease.

作者信息

Mannucci P M

机构信息

Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Department of Internal Medicine, IRCCS Maggiore Hospital and University of Milan, Italy.

出版信息

Thromb Haemost. 2002 Sep;88(3):378-9.

PMID:12353063
Abstract
摘要

相似文献

1
Venous thromboembolism in von Willebrand disease.
Thromb Haemost. 2002 Sep;88(3):378-9.
2
Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease.使用中间纯度的凝血因子VIII浓缩物治疗血管性血友病患者后发生的静脉血栓形成。
Thromb Haemost. 2002 Sep;88(3):387-8.
3
Thromboembolic incidence with transiently elevated levels of coagulation factors in patients with von Willebrand disease treated with VWF:FVIII concentrate during surgery.在手术期间接受血管性血友病因子：凝血因子VIII浓缩物治疗的血管性血友病患者中，凝血因子水平短暂升高时的血栓栓塞发生率。
Haemophilia. 2014 Nov;20(6):e404-6. doi: 10.1111/hae.12498. Epub 2014 Aug 12.
4
von Willebrand disease: treatment with or without factor VIII?血管性血友病：使用或不使用凝血因子 VIII 进行治疗？
J Thromb Haemost. 2007 Jun;5(6):1113-4. doi: 10.1111/j.1538-7836.2007.02560.x.
5
Human plasma von Willebrand factor/factor VIII complex (Haemate P/Humate-P): in von Willebrand disease and haemophilia A.人血浆血管性血友病因子/凝血因子 VIII 复合物（海莫莱士/人凝血因子 VIII）：用于血管性血友病和甲型血友病。
Drugs. 2007;67(10):1513-9. doi: 10.2165/00003495-200767100-00009.
6
Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.血管性血友病急性出血的治疗与预防——新一代血管性血友病因子/凝血因子VIII浓缩物Wilate的疗效与安全性
Haemophilia. 2009 Jan;15(1):122-30. doi: 10.1111/j.1365-2516.2008.01901.x.
7
Management of von Willebrand's disease.
Prog Clin Biol Res. 1990;324:279-90.
8
Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate®): a single centre experience.血管性血友病因子/凝血因子VIII浓缩剂（Wilate®）的安全性和有效性：单中心经验
Haemophilia. 2014 Nov;20(6):846-53. doi: 10.1111/hae.12496. Epub 2014 Aug 7.
9
Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.血管性血友病因子/凝血因子VIII浓缩物在血管性血友病治疗中的应用
Blood Coagul Fibrinolysis. 2009 Mar;20(2):89-100. doi: 10.1097/MBC.0b013e3283254570.
10
[Treatment of a hemorrhagic syndrome in severe von Willebrand disease in the presence of circulating anti-von-Willebrand-factor antibody].[存在循环抗血管性血友病因子抗体时严重血管性血友病出血综合征的治疗]
Med Clin (Barc). 1988 May 28;91(1):28-30.

引用本文的文献

1
Bilateral total knee replacement for hemophilic arthropathy: a case report.血友病性关节病的双侧全膝关节置换术：一例报告
BMC Musculoskelet Disord. 2025 Apr 25;26(1):417. doi: 10.1186/s12891-025-08611-1.
2
Preoperative risk factors for venous thromboembolism in major urologic cancer surgeries.主要泌尿外科癌症手术中静脉血栓栓塞的术前危险因素。
World J Urol. 2024 Dec 4;43(1):10. doi: 10.1007/s00345-024-05372-9.
3
Real-World Efficacy and Safety of Plasma-Derived Von Willebrand Factor-Containing Factor VIII Concentrates in Patients With Von Willebrand Disease in Italy.
意大利血管性血友病患者中血浆源性含血管性血友病因子的凝血因子VIII浓缩物的真实世界疗效和安全性
Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241264541. doi: 10.1177/10760296241264541. Epub 2024 Jul 21.
4
Prophylactic management of patients with von Willebrand disease.血管性血友病患者的预防性管理。
Ther Adv Hematol. 2021 Dec 22;12:20406207211064064. doi: 10.1177/20406207211064064. eCollection 2021.
5
Real-World Data on the Effectiveness and Safety of wilate for the Treatment of von Willebrand Disease.关于威尔特（wilate）治疗血管性血友病有效性和安全性的真实世界数据。
TH Open. 2021 Jul 4;5(3):e264-e272. doi: 10.1055/s-0041-1730283. eCollection 2021 Jul.
6
An Open-Label Extension Study to Assess the Long-Term Efficacy and Safety of a Plasma-Derived von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Patients with von Willebrand Disease (SWIFT-VWDext Study).一项开放标签扩展研究，旨在评估血浆源性血管性血友病因子（VWF）/凝血因子VIII（FVIII）浓缩物在血管性血友病患者中的长期疗效和安全性（SWIFT-VWDext研究）。
J Blood Med. 2020 Oct 9;11:345-356. doi: 10.2147/JBM.S268907. eCollection 2020.
7
Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVIII Concentrate (Formulation V) in Pediatric Patients with von Willebrand Disease (SWIFTLY-VWD Study).血浆源性血管性血友病因子/凝血因子VIII浓缩物（制剂V）在儿童血管性血友病患者中的药代动力学、疗效和安全性（SWIFTLY-VWD研究）
J Blood Med. 2020 Jun 22;11:213-225. doi: 10.2147/JBM.S236789. eCollection 2020.
8
Management of von Willebrand disease with a factor VIII-poor von Willebrand factor concentrate: Results from a prospective observational post-marketing study.使用低VIII因子血管性血友病因子浓缩物治疗血管性血友病：一项上市后前瞻性观察研究的结果
J Thromb Haemost. 2020 Aug;18(8):1922-1933. doi: 10.1111/jth.14928. Epub 2020 Jun 25.
9
Evidence-Based Minireview: Perioperative management of the VWD patient at elevated thrombotic risk.循证医学小综述：血栓形成风险升高的血管性血友病（VWD）患者的围手术期管理
Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):601-603. doi: 10.1182/hematology.2019000078.
10
Pregnancy and delivery in women with von Willebrand disease.妊娠与分娩：患有血管性血友病妇女的应对策略。
Eur J Haematol. 2019 Aug;103(2):73-79. doi: 10.1111/ejh.13250. Epub 2019 May 31.